Molécules inhibitrices des récepteurs du VEGF

Jeanette M Wood, G Bold, Elizabeth Buchdunger, R Cozens, Stefano Ferrari, Jörg Frei, F Hofmann, Jürgen Mestan, H Mett, Terence O’Reilly, Elke Persohn, Johannes Rösel, Christian Schnell, David Stover, A Theuer, Harry Towbin, Fritz Wenger, K Woods-Cook, A Menrad, Gerhard Siemeister, M Schirner, Karl-Heinz Thierauch, Martin R Schneider, J Drevs, G Martiny-Baron, F Totzke, Dieter Marmé, PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration Cancer Research. ,vol. 60, pp. 2178- 2189 ,(2000)

P. H. De Mulder, J. Roigas, S. Gillessen, S. Srinivas, P. Pisa, N. Vogelzang, G. Fountzilas, C. Peschel, C. Baum, B. Escudier, A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology. ,vol. 24, pp. 4529- 4529 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.4529

Karri Paavonen, Pauli Puolakkainen, Lotta Jussila, Tiina Jahkola, Kari Alitalo, None, Vascular Endothelial Growth Factor Receptor-3 in Lymphangiogenesis in Wound Healing American Journal of Pathology. ,vol. 156, pp. 1499- 1504 ,(2000) , 10.1016/S0002-9440(10)65021-3

Roger B. Cohen, Corey J. Langer, George Rajan Simon, Peter David Eisenberg, John Daniel Hainsworth, Stefan Madajewicz, Thomas Michael Cosgriff, Kristen Pierce, Huiping Xu, Katherine Liau, Diane Healey, A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC) Cancer Chemotherapy and Pharmacology. ,vol. 60, pp. 81- 89 ,(2007) , 10.1007/S00280-006-0352-0

A. Tolcher, J.J. O'Leary, J. DeBono, K. Molpus, C. Woodard, M. Warnat, K. Liau, D. Noe, D. Healey, M. Huberman, 137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors Ejc Supplements. ,vol. 2, pp. 44- ,(2004) , 10.1016/S1359-6349(04)80145-9

Bernard Escudier, Tim Eisen, Walter M Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Negrier, Christine Chevreau, Ewa Solska, Apurva A Desai, Frédéric Rolland, Tomasz Demkow, Thomas E Hutson, Martin Gore, Scott Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M Bukowski, None, Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 125- 134 ,(2007) , 10.1056/NEJMOA060655

Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter, None, The biology of VEGF and its receptors. Nature Medicine. ,vol. 9, pp. 669- 676 ,(2003) , 10.1038/NM0603-669

T Eisen, T Ahmad, K T Flaherty, M Gore, S Kaye, R Marais, I Gibbens, S Hackett, M James, L M Schuchter, K L Nathanson, C Xia, R Simantov, B Schwartz, M Poulin-Costello, P J O'Dwyer, M J Ratain, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis British Journal of Cancer. ,vol. 95, pp. 581- 586 ,(2006) , 10.1038/SJ.BJC.6603291

Shay Soker, Seiji Takashima, Hua Quan Miao, Gera Neufeld, Michael Klagsbrun, Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor Cell. ,vol. 92, pp. 735- 745 ,(1998) , 10.1016/S0092-8674(00)81402-6

Hope S. Rugo, Roy S. Herbst, Glenn Liu, John W. Park, Merrill S. Kies, Heidi M. Steinfeldt, Yazdi K. Pithavala, Steven D. Reich, James L. Freddo, George Wilding, Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results Journal of Clinical Oncology. ,vol. 23, pp. 5474- 5483 ,(2005) , 10.1200/JCO.2005.04.192